LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.01

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$219.79M
EPS-2.8500
P/E Ratio-2.46
Earnings Date07/29/2026

lenz

Total Current Assets

Last Annual Value

292.35M

3-Year CAGR

84%

5-Year CAGR

69%

10-Year CAGR

194%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Total Current Assets

LENZ · NASDAQ
CompanyTotal Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
292.35M
63.2%74.0%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
241.62M
13.3%7.9%32.4%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
171.15M
17.7%32.4%43.9%
284.90M
7.2%36.2%N/A
94.46M
-10.6%-10.1%-3.3%
520.27M
15.1%22.7%16.2%
296.25M
-24.9%-16.7%N/A
265.45M
7.8%-2.7%N/A
181.29M
8.2%-7.7%N/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.01, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.01